Monday, October 3, 2022
News
NEWS HOME
»
PRN INDIA
Novaliq submits New Drug Application seeking approval for first-of-a-kind Dry Eye Disease Treatment CyclASol®
  SocialTwist Tell-a-Friend  
   

HEIDELBERG, Germany, and CAMBRIDGE, MA, Aug. 9, 2022 /PRNewswire/ -- Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol ® water-free technology, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for CyclASol ® (cyclosporine ophthalmic solution), a proposed novel treatment for the signs and symptoms of dry eye disease (DED).

Novaliq GmbH Logo

 

CyclASol ® has demonstrated in two pivotal studies fast onset of therapeutic effect in the indication, clinical meaningful improvement of ocular surface damage, and excellent tolerability. Results from a 12-month long-term study confirmed that the effects are maintained, and even improved for most sign and symptom endpoints.

"This is the first submission of a novel product category of water-free topical drug therapies utilizing EyeSol ® as a drug carrier", said Christian Roesky, Ph.D., CEO, Novaliq. "CyclASol ® is a first-of-a-kind drug therapy and aims to expand treatment success for patients with dry eye disease and their eye care professionals. If approved by the FDA, CyclASol ® addresses important unmet medical needs in DED through its ocular surface healing effect combined with high comfort of administration."

Dry eye is one of the most common ocular surface disorders, with approximately 18 million Americans diagnosed with DED.1,2 Inflammation and immunologic processes play a key role in the pathology of the disease.

A compromised ocular surface secondary to DED may also compromise refractive measurements before keratorefractive and phacorefractive surgeries and adversely impact expected visual outcomes after these surgeries.3,4 The impact of the corneal surface damage secondary to DED on visual function is an underestimated aspect of the disease. Multiple guidelines recommend treatment of the corneal surface damage prior to ocular procedures. A high unmet need remains for better tolerated drugs with an early onset of therapeutic effect, which are compelling to be used and prescribed.5,6

"We are very proud to see another product rapidly moving to the market, which marks yet another important inflection point and milestone in Novaliq's growth trajectory", said Dr. Mathias Hothum, board member and managing director of dievini. "We are currently evaluating the commercialization strategies which includes talking to interested parties."

About CyclASol ®  
CyclASol ® is a first-of-a-kind topical treatment of cyclosporine, a potent anti-inflammatory and selective immunomodulatory drug. Whilst not water-soluble, cyclosporine is soluble in the EyeSol ® excipient perfluorobutylpentane allowing for its improved bioavailability and better efficacy on the target tissue.   The product contains no oils, no surfactants and is preservative-free due to the novel carrier. This provides additional clinical benefits for patients, such as improved tolerability and decreased visual disturbances.

The NDA is supported by safety and efficacy results in over 1,000 patients with DED from a Phase 2 dose finding study, the Phase 2b/3 ESSENCE-1 study, the Phase 3 ESSENCE-2 study and its open label extension study.7,8

CyclASol ® has demonstrated in two independent adequate and well-controlled, multicenter studies (ESSENCE-1 and ESSENCE-2) clinically meaningful and statistically significant improvements in the indication.

Effects on the ocular surface  include a statistically significant reduction in total corneal fluorescein staining (tCFS) score favoring CyclASol ® in both studies at Days 15 and 29. Up to 71.6% of patients  responded within four weeks with a clinically meaningful improvement of ≥ 3 grades in total corneal staining. This proportion of responders was significantly higher compared to vehicle-treated patients in both studies. Responders showed also statistically significant improvements in a variety of symptoms compared to non-responders at day 29. The ASCRS guidelines recognize corneal staining as the single most important clinical sign of DED as it indicates the level of epithelial damage and visual impairment, and if left undertreated, DED can become chronic and more difficult to treat.3

Effect on tear production: In both studies, compared to vehicle at the end of treatment, there was a statistically significant (p<0.05) higher percentage of patients  with increases of ≥  10 mm from baseline in Schirmer's tear test score at Day 85 and Day 29, respectively, confirming a known effect of the active ingredient cyclosporine. Meeting this endpoint in two independent studies is clinically meaningful on its own and considered to demonstrate efficacy for the treatment of signs and symptoms of DED.

Head-to-head data  versus Restasisâ„¢  from the phase 2 study suggest that CyclASol ® has a stronger and faster therapeutic effect on the ocular surface.8

Maintenance of effect  results from the long-term study CYS-005 confirmed that the effect of CyclASol ® was maintained, and even improved for most endpoints, over the 52-week treatment period.

Safety and Tolerability: Tolerability of CyclASol ® was shown by high drop comfort patient ratings in both studies. The most common adverse reaction observed was instillation site reactions, which was reported in 8.1% of patients in the pooled studies. These were in all but one case mild. The only other adverse reaction reported in > 2% of the patients was visual acuity reduced (2.7%).

About Novaliq
Novaliq is a biopharmaceutical company focusing on the development and commercialization of first- and best-in-class ocular therapeutics based on EyeSol ®, the worldwide first water-free technology.

EyeSol ® is Novaliq's proprietary water-free technology using ultrapure semifluorinated alkanes (SFAs) that are physically, chemically, and physiologically inert with excellent biocompatibility and a very good safety profile. Novaliq offers an industry-leading portfolio addressing today's unmet medical needs of millions of patients with eye diseases.

In July 2022 submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) was announced seeking approval for NOV03 (perfluorohexyloctane), for the proposed indication of treating the signs and symptoms of dry eye disease (DED) associated with Meibomian gland dysfunction (MGD). In addition to CyclASol ®, the company continues to progress multiple additional pipeline opportunities based on its validated EyeSol ® platform, both in ophthalmology and adjacent indications like dermatology.

Novaliq GmbH is headquartered in Heidelberg, Germany and Novaliq Inc. has an office in Cambridge, MA, USA. The long-term shareholder is dievini Hopp BioTech holding GmbH & Co. KG, an active investor in Life and Health Sciences companies. More on www.novaliq.com.  

Recommended Readings

  1. Leonardi A, Modugno RL, & Salami E. Allergy and Dry Eye Disease. Ocular immunology and inflammation. 2021; 29:1168–1176
  2. 2020 Dry Eye Products Market Report: A global Analysis for 2019 to 2025. Market Scope
  3. Starr CE, Gupta PK, Farid M, Beckman KA, Chan CC, Yeu E, Gomes JAP, Ayers BD, Berdahl  JP, Holland EJ, Kim T, Mah FS  (the ASCRS  Cornea Clinical Committee). An algorithm for the preoperative diagnosis and treatment of ocular surface disorders. J  Cataract Refract Surg. 2019; 45:669–684
  4. Donaldson K, Parkhurst  G, Saenz  B, Whitley W, Williamson B, Hovanesian J. Call to action: treating dry eye disease and setting the foundation for successful surgery. J  Cataract Refract Surg. 2022; 48:623–629
  5. White DE, Zhao Y, Ogundele  A, Fulcher N, Acs  A, Moore-Schiltz L, Karpecki  PM. Real-World Treatment Patterns Of Cyclosporine  Ophthalmic Emulsion And Lifitegrast  Ophthalmic Solution Among Patients With Dry Eye. Clin Ophthalmol. 2019; 13:2285-2292
  6. Dunn JD, Karpecki  PM, Meske  ME, Reissman  D. Evolving knowledge of the unmet needs in dry eye disease. Am J Manag  Care. 2021; 27:S23-32
  7. Sheppard JD, Wirta  DL, McLaurin E, Boehmer  BE, Ciolino  CB, Meides  AS, Schlüter T, Ousler GW, Usner  D,   Krösser  S. A Water-free 0.1% Cyclosporine  A Solution for Treatment of Dry Eye Disease: Results of the Randomized Phase II/III ESSENCE Study. Cornea. 2021; 40:1290-1297
  8. Wirta  DL, Torkildsen GL, Moreira  HR, Lonsdale JD, Ciolino JB, Jentsch  G, Beckert M, Ousler  GM, Steven P, Krösser  S. A Clinical Phase II Study to Assess Efficacy, Safety, and Tolerability of Waterfree Cyclosporine  Formulation for Treatment of Dry Eye Disease. Ophthalmology. 2019; 126:793-800

Any product/brand names and/or logos are trademarks of the respective owners.   © 2022 Novaliq GmbH, Heidelberg, Germany.

Novaliq Media Contact:
Simone Angstmann-Mehr
info@novaliq.com
+49 6221 50259-0

Logo: https://mma.prnewswire.com/media/1804666/Novaliq_GmbH_Logo.jpg

More News by PR Newswire India

Azure Power wins the prestigious Golden Peacock Award for Sustainability

FANDOM ACQUIRES LEADING ENTERTAINMENT & GAMING BRANDS INCLUDING GAMESPOT, TV GUIDE AND METACRITIC

National Engineering Industries Ltd (NBC Bearings) honored with 'Iconic Brands of India 2022'

Celebrating Glorious 35 Years of BIMTECH

HABANOS, S.A. PRESENTED THE MONTECRISTO WIDE EDMUNDO IN WORLD PREMIERE IN SPAIN

Sanjay Ghodawat Foundation awarded The Mahatma Award 2022

STL announces Gram Galaxy - India's first integrated solution to connect villages with fibre

DEBIOPHARM REINFORCES THE BOND BETWEEN SWISS AND JAPANESE CANCER RESEARCH WITH THE 2022 JCA MAUVERNAY AWARD CEREMONY

Healthium Medtech amongst the first in Asia and first Indian Medtech Company to receive CE certification under the EU MDR (European Union Medical Device Regulation) norms for Class III implants

Jagadguru Kripalu Parishat holds Grand Rath Yatra on 3rd October 2022 near Kunda, Pratapgarh in honor of the 100th Birth Anniversary of Jagadguru Shri Kripalu Ji Maharaj

Addteq APAC Announces Rebranding, Changes Name to Enreap

Karwa Chauth 2022: FlowerAura Is All Geared Up To Enhance The Celebrations

DMCC AWARDED GLOBAL FREE ZONE OF THE YEAR FOR EIGHTH CONSECUTIVE YEAR

New Book Property Tax in Asia Provides the First Comprehensive Analysis of the Property Tax Across the World's Largest Continent

UN WOMEN'S HeForShe EXPANDS MOVEMENT THROUGH KEY PUBLIC AND PRIVATE PARTNERSHIPS IN EAST ASIA

STL unveils 5G cosmos to help Indian telcos fiberise their networks for 5G

STL launches Multiverse - India's first Multicore fibre and cable; aims to revolutionize the optical landscape

Tejas Networks successfully demonstrates end-to-end network based on its indigenous 4G/5G wireless, optical and satellite products

IIIT Hyderabad and Silicon Labs Launch Campus-wide Wi-SUN Network for Smart City Applications

 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
INDIA WORLD ASIA
Oct 5 is D-Day for KCR's national party ...
Kanya Pujan 2022: Significance, Puja tim...
Bihar: Agriculture Minister Sudhakar Sin...
Durga Puja pandal fire in Uttar Pradesh'...
7-yr-old dies after electric scooter's b...
3 dead in Durga Puja pandal fire in UP's...
More...    
 
 Top Stories
Adam Levine's wife supports him at ... 
US East-Coast: The Seaboard of comm... 
SIIB organizes its flagship event t... 
Sonia Gandhi arrives in Mysuru for ... 
Fertiliser firms seek to buy phosph... 
SC remarks petition seeking relief ... 
BPCL recognized as the Most Preferr... 
Mozart Automobile launching first e...